BRI3BP and hepatocellular carcinoma: Collectively, the analyses demonstrate that BRI3BP offers robust prognostic discrimination and may predict sensitivity to targeted agents such as lapatinib in preclinical models, supporting its candidacy as a prognostic biomarker and potential therapeutic target in HCC—pending further experimental confirmation.